Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0Q1HD
|
|||
Drug Name |
TRV250
|
|||
Indication | Migraine [ICD-11: 8A80; ICD-10: G43, G43.9; ICD-9: 346] | Phase 1 | [1] | |
Company |
Trevena Chesterbrook, PA
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Opioid receptor delta (OPRD1) | Target Info | Modulator | [1] |
KEGG Pathway | cGMP-PKG signaling pathway | |||
Sphingolipid signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Enkephalin release | ||||
Opioid proenkephalin pathway | ||||
Opioid proopiomelanocortin pathway | ||||
Reactome | Peptide ligand-binding receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | GPCRs, Class A Rhodopsin-like | |||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.